Abstract
Data from clinical trials highlighted the potential and pitfalls of the use of biologics to treat systemic lupus erythematosus. With improved understanding of immunopathogenesis and lessons learned from controlled trials, there is a growing optimism for personalized treatment from an increasing range of targeted therapies.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Biological Products / therapeutic use*
-
Humans
-
Immunologic Factors / therapeutic use*
-
Lupus Erythematosus, Systemic / drug therapy*
-
Lupus Erythematosus, Systemic / etiology
-
Lupus Erythematosus, Systemic / pathology
-
Molecular Targeted Therapy*
Substances
-
Biological Products
-
Immunologic Factors